Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions

Journal of Immunology

Volumn 166, Issue 11, 2001, Pages 6720-6727

  Godkin, Andrew J ^a,e   Smith, Kathrine J ^b   Willis, Anthony ^c   Tejada Simon, Maria V ^d   Zhang, Jingwu ^d   Elliott, Tim ^a   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA DR2 ANTIGEN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CELL ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE;

EID: 0035338992     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.11.6720     Document Type: Article

References (35)

1. Rammensee, H.-G. 1995. Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 7:85.
2. Stern, L., J. Brown, T. Jardetzky, J. Gorga, R. Urban, J. Strominger, and D. Wiley. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215.
3. Ghosh, P., M. Amaya, E. Mellins, and D. Wiley. 1995. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378:457.
4. Dessen, A., M. Lawrence, S. Cupo, D. Zaller, and D. Wiley. 1997. X-ray crystal structure of HLA-DR4(DRA*0101, B1*0401) complexed with a peptide from human collagen II. Immunity 7:473.
5. Smith, K., J. Pyrdol, L. Gauthier, D. Wiley, and K. Wucherpfennig. 1998. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 188:1511.
6. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1994. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 39:230.
7. Friede, T., V. Gnau, G. Jung, W. Keilholz, S. Stevanovic, and H.-G. Rammensee. 1996. Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides. Biochim. Biophys. Acta 1316: 85.
8. Godkin, A., T. Friede, M. Davenport, S. Stevanovic, A. Willis, J. Jewell, A. Hill, and H.-G. Rammensee. 1997. Use of eluted peptide sequence data to identify the binding characteristics of peptides to the insulin-dependant diabetes susceptibility allele HLA-DQ8 (DQ 3.2). Int. Immunol. 9:905.
9. Godkin, A., M. Davenport, A. Willis, D. Jewell, and A. Hill. 1998. Use of complete eluted peptide sequence data from HLA-DR and -DQ molecules to predict T-cell epitopes, and the influence of the nonbinding terminal regions of ligands in epitope selection. J. Immunol. 161:850.
10. Malcherek, G., V. Gnau, G. Jung, H.-G. Rammensee, and A. Melms. 1995. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules. J. Exp. Med. 181:527.
11. Rotzschke, O., K. Falk, J. Lau, G. Jung, and J. Strominger. 1999. Conformation variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes. Proc. Natl. Sci. USA 96:7445.
12. Moudgil, K., E. Sercarz, and I. Grewal. 1998. Modulation of the immunogenicity of antigenic determinants by their flanking residues. Immunol. Today 19:217.
13. Carson, R., K. Vignali, D. Woodland, and D. Vignali. 1997. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. Immunity 7:387.
14. Wucherpfennig, K., A. Sette, S. Southwood, C. Oseroff, M. Matsui, J. Strominger, and D. Hafler. 1994. Structural requirements for binding of an immunodominant myelin basic peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179:279.
15. Olerup, O., S. Hillert, S. Fredrickson, T. Olsson, E. Kam-Hansen, B. Carlsson, and J. Wallin. 1989. Primary chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc. Natl. Acad. Sci. USA 86:7113.
16. Vogt, A., H. Kropshofer, H. Kalbacher, M. Kalbus, H.-G. Rammensee, J. Coligan, and R. Martin. 1994. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J. Immunol. 153:1665.
17. Ota, K., M. Matsui, E. Milford, G. Mackin, H. Weiner, and D. Hafler. 1990. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346:183.
18. Hemmer, B., B. Fleckenstein, M. Vergelli, G. Jung, H. McFarland, R. Martin, and K.-H. Wiesmuller. 1997. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T-cell clone. J. Exp. Med. 185:1651.
19. Kozovska, M., Y. Zang, I. Aebischer, S. Lnu, V. Rivera, P. Crowe, S. Boehme, and J. Zhang. 1998. T cell recognition motifs of an immunodominant peptide of myelin basic protein in patients with multiple sclerosis: structural requirements and clinical implications. Eur. J. Immunol. 28:1894.
20. Fleckenstein, B., H. Kalbacher, C. Muller, D. Stoll, T. Halder, G. Jung, and K.-H. Wiesmuller. 1996. New ligands binding to the human leukocyte antigen class II molecule DRB1*0101 based on the activity pattern of an undecapeptide library. Eur. J. Biochem. 240:71.
21. Gorga, J. C., V. Horejsi, D. R. Johnson, R. Raghupathy, and J. L. Strominger. 1987. Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. J. Biol. Chem. 262:16087.
22. Robbins, P., E. Evans, A. Ding, N. Warner, and F. Brodsky. 1987. Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes. Hum. Immunol. 18:301.
23. Davenport, M., I. Ho Shon, and A. Hill. 1995. An empirical method for the prediction of T-cell epitopes. Immunogenetics 42:392.
24. Davenport, M., C. Quinn, R. Chicz, B. Green, A. Willis, W. Lane, J. Bell, and A. Hill. 1995. Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR β chain. Proc. Natl. Acad. Sci. USA 92:6567.
25. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
26. Nelson, C., I. Vidavsky, N. Viner, M. Gross, and E. Unanue. 1997. Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 94:628.
27. Arnold, D., W. Keilholz, H. Schild, T. Dumreses, S. Stevanovic, and H.-G. Rammensee. 1997. Substrate specificity of cathepsins D and E determined by N-terminal and C-terminal sequencing of peptide pools. Eur. J. Biochem. 1:171.
28. Davenport, M., A. Godkin, T. Friede, S. Stevanovich, A. Willis, A. Hill, and H.-G. Rammensee. 1997. A distinctive binding motif for HLA-DRB1*0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. Immunogenetics 45: 229.
29. Wucherpfennig, K., and J. Strominger. 1995. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695.
30. O'Sullivan, D., T. Arrhenius, J. Sidney, G. M. Del, M. Albertson, M. Wall, C. Oseroff, S. Southwood, S. M. Colon, F. C. Gaeta, and et al. 1991. On the interaction of promiscuous antigenic peptides with different DR alleles: identification of common structural motifs. J. Immunol. 147:2663.
31. Reinherz, E., K. Tan, L. Tang, P. Kern, J. Liu, Y. Xiong, R. Hussey, A. Smolyar, and B. Hare. 1999. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286:1913.
32. Sercarz, E., P. Lehmann, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1993. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11:729.
33. Schneider, S., J. Ohmen, L. Fosdick, B. Gladstone, J. Guo, A. Ametani, E. Sercarz, and H. Deng. 2000. Cutting edge: introduction of an endopeptidase cleavage motif into a determinant flanking region of hen egg lysozyme results in enhanced T cell determinant display. J. Immunol. 165:20.
34. Cope, A., S. Patel, F. Hall, M. Congia, H. Hubers, G. Verheijden, A. Boots, R. Menon, M. Trucco, A. Rijinders, and G. Sonderstrup. 1999. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. Arthritis Rheum. 42:1497.
35. Matsuo, H., A.-P. Batocchi, S. Hawke, M. Nicolle, L. Jacobson, A. Vincent, J. Newsome-Davis, and N. Willcox. 1995. Peptide-selected T cell lines from myasthenia gravis patients and controls recognise epitopes that are not processed from whole acetylcholine receptor. J. Immunol. 155:3683.